Table 3.
Noncompartmental Pharmacokinetic Parameters After Repeat Doses of Oral Cabotegravir 150 mg in Healthy Subjects
| Cabotegravir 150 mg Every 12 Hours × 3 Dosesa | |||
|---|---|---|---|
| Parameter | Women (n = 9) | Men (n = 31) | All Subjects (n = 40) |
| Cmax (μg/mL), geometric mean (CV,%) [90%CI] | 25.1 (22) [21.2–29.6] | 21.9 (19) [20.4–23.4] | 22.5 (20) [21.1–24.0] |
| AUC0–12 (μg·h/mL), geometric mean (CV,%) [90%CI] | 234 (22) [198–277] | 213 (15) [202–225] | 217 (17) [206–229] |
| AUC0–24 (μg·h/mL), geometric mean (CV,%) [90%CI] | 409 (22) [345–484] | 380 (15) [359–402] | 386 (17) [366–408] |
| tmax (h), median (range) | 2.0 (1.0–4.0) | 2.0 (1.0–4.0) | 2.0 (1.0–4.0) |
AUC0–12, area under the plasma concentration–time curve from 0 to 12 hours; AUC0–24, AUC from 0 to 24 hours; CI, confidence interval; Cmax, maximum observed plasma concentration; CV, coefficient of variation (ratio of the standard deviation to the mean); tmax, time to Cmax.
a
Three doses of cabotegravir 150 mg (5 × 30‐mg tablets) every 12 hours.